ABC News October 29, 2021

FDA authorizes COVID-19 vaccine for kids 5-11

WATCH: FDA authorizes COVID-19 vaccine for children 5 to 11

Another 28 million Americans are one step closer to getting vaccinated against COVID-19 after the Food and Drug Administration on Friday authorized the Pfizer shot for 5- to 11-year-olds.

Children will be one of the last groups in the U.S. to become eligible for the vaccine. Protecting them against COVID-19 is a major step in getting the country back on the path to normalcy after an unexpected late-summer surge that disproportionately impacted unvaccinated Americans and filled hospitals to the brim.

"The rationale here is protect your children so that they can get back towards normal lives," said Dr. Peter Marks, the FDA's vaccine chief, in a press conference after the authorization was announced.

"The tremendous cost of this pandemic has not just been in physical illness, it's been in the psychological the social development of children."

The process now heads to the Centers for Disease Control and Prevention. An advisory committee for the CDC will meet on Tuesday to discuss the pediatric vaccine safety and efficacy data, as an advisory FDA panel did this past week, and then CDC Director Rochelle Walensky is expected to give the final signoff soon afterward.

That means kids could begin getting shots at some point next week and become fully vaccinated by December.

In anticipation, the White House planned to unleash millions of vaccine shipments across the nation as soon as FDA authorization was announced. Vaccine sites will have to wait for the CDC's word to begin administering the vaccine, but stock will be on hand.

MORE: FDA panel greenlights vaccines for kids, paving the way for authorization

"The bottom line is that we will be ready immediately following FDA and CDC decisions so that parents can get their kids vaccinated quickly, easily and conveniently," White House COVID-19 coordinator Jeff Zients said at a briefing with reporters on Thursday.

The White House purchased enough shots for all 28 million 5-11 year olds and on Thursday announced plans to purchase another 50 million shots by April 30, 2022, which could also be used for children under 5, if and when there is authorization for that age group.

The vaccines will be available at pharmacies, pediatricians' offices, family doctors, community sites, schools and other local locations, the White House said, in an effort to make sure parents are comfortable and can get their kids vaccinated by trusted health care providers.

In a statement heralding the authorization, the American Academy of Pediatrics President Lee Savio Beers said pediatricians were "standing by to talk with families about the vaccine and to administer the vaccine to children as soon as possible.”

“Authorization of the vaccine for younger children is an important step in keeping them healthy and providing their families with peace of mind. The vaccine will make it safe for children to visit friends and family members, celebrate holiday gatherings, and to resume the normal childhood activities that they’ve missed during the pandemic," Beers said.

Pfizer via Reuters
An undated handout photo shows vials of Pfizer/BioNTech's new pediatric Covid-19 vaccine.

Though there was some debate at the FDA advisory meeting about the potential side effects for children 5-11 -- particularly because myocarditis, a condition involving inflammation of the heart, has been linked to the vaccine in teenage boys and young men -- the panel nearly unanimously voted in favor of the vaccine, deciding that the risk was worth the benefit.

None of the 3,100 kids who received the Pfizer-BioNTech pediatric vaccine in the clinical trials have experienced serious side effects, including myocarditis.

Meanwhile, nearly 2 million kids ages 5-11 have gotten COVID, and 8,300 have been hospitalized with COVID-19. A third of those children ended up in the ICU and over 100 have died.

"To me the question is pretty clear. We don't want children to be dying of COVID, even if it is far fewer children than adults, and we don't want them in the ICU," Dr. Amanda Cohn, an epidemiologist with the CDC, said at the FDA meeting on Tuesday.

Dr. William Gruber, the senior vice president of Pfizer Vaccine Clinical Research and Development, told ABC News in an interview Friday that he also saw the vaccine as a way to protect children from the emotional instability the virus has wrought. Widespread vaccination could keep children out of quarantine after being exposed at school and ensure the safety of indoor activities ahead of the winter.

Shawn Rocco/Duke University via Reuters
Lydia Melo, 7, is inoculated with one of two reduced 10 ug doses of the Pfizer BioNtech COVID-19 vaccine during a trial at Duke University in Durham, N.C., Sept. 28, 2021.

He pointed to the benefits of "allowing children to be children."

"This allows that to open up again, we've been seeing step-by-step progress and opening up society. It's time for that to happen with children as well," Gruber said.

MORE: FDA panel greenlights vaccines for kids, paving the way for authorization

Whether parents will embrace the vaccines for their kids is still a question. In an October poll, the Kaiser Family Foundation found that about a third of parents with kids ages 5-11 were willing to vaccinate their kids right away, while another third wanted to "wait and see." The figures represented a slight uptick in vaccine acceptance among parents of elementary-school-aged kids since July, but they have stayed steady since September.

FDA acting commissioner Janet Woodcock told reporters on Friday that she hoped parents would quickly see the benefits.

"We certainly hope that as people see children getting vaccinated and being protected, being able to participate in activities without concern, that more and more people will get their kids vaccinated," she said.

And she emphasized the urgency of preventing the conditions that can come with COVID diagnoses in kids.

"As a parent, if I had young children this age group I would get them vaccinated now. I would not want to take the risk that they would be one of the ones who would develop long COVID, who would develop multi-system inflammatory syndrome or have to be hospitalized from from the virus," Woodcock said.